GlassScriptPhysician profile
Vikas Bhushan
NPI 1285677138
$15,580.49
in general payments reported to CMS, 2019-2025
17 companies · $80.61 in 2025
The $80.61 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,252 · 2020: $1,769 · 2021: $4,660 · 2022: $165 · 2023: $1,854 · 2024: $1,799 · 2025: $80.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,558 · Food and Beverage: $150 · Education: $26.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,558.00 |
| Food and Beverage | $149.81 |
| Education | $26.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,573.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $3,558.00 | 2023-2024 | |
| Kite Pharma, INC. | $1,737.45 | 2021-2024 | Yescarta |
| Celgene Corporation | $1,695.00 | 2020 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Epizyme, INC. | $1,000.00 | 2021 | |
| Astellas Pharma US INC | $189.12 | 2019-2025 | Xospata |
| Janssen Scientific Affairs, LLC | $113.31 | 2022 | |
| Pharming Healthcare, INC. | $78.00 | 2022-2023 | |
| Abbvie INC. | $30.95 | 2025 | |
| Boston Scientific Corporation | $18.49 | 2023 | Wavewriter Alpha Prime 16 |
| Pharmacyclics LLC, An Abbvie Company | $13.26 | 2023 | Imbruvica |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Bhushan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.